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bjectives We sought to examine angiographic and clinical outcomes with sirolimus-eluting stents
SES) in total coronary occlusion (TCO) revascularization.
ackground Despite evaluation of drug-eluting stents beyond approved indications, few studies
ave evaluated their clinical beneﬁt in TCO revascularization.
ethods Among 15 centers in North America, 200 consecutive TCO patients (78.8% 6 weeks TCO
ge) were enrolled for treatment with SES. The primary end point was 6-month angiographic binary
estenosis within the treated segment.
esults Patient characteristics included: diabetes, 24.5%; prior infarction, 33.5%; and stent length, 45.9
m median (quartile 1, 30.2 mm; quartile 2, 62.1 mm). A total of 199 patients (99.5%) were treated with
ES, and procedural success was 98.0%. The 6-month binary restenosis rates were 9.5% in-stent, 12.4%
n-segment, and 22.6% in-“working length” representing the entire treatment segment. Rates of 1-year
arget lesion revascularization, myocardial infarction, and target vessel failure were 9.8%, 1.0%, and
0.9%, respectively. Stent thrombosis occurred in 2 patients (1.0%). Using logistic regression modeling
ith propensity score adjustment, the absolute reduction in binary restenosis with SES compared with a
istorical bare-metal stent control was 37.7% (95% conﬁdence interval [CI]: 27.2% to 48.3%, p  0.001;
dds ratio: 0.17, 95% CI: 0.09 to 0.30, p  0.0001). Among 32 patients (16%) identiﬁed with stent frac-
ure, target lesion revascularization was more common than patients without fracture (25.0% vs. 6.7%,
 0.005).
onclusions Despite greater lesion complexity than prior TCO trials, percutaneous revascularization
ith SES appears safe and results in substantial reductions in angiographic restenosis and failed pa-
ency and a low rate of repeat revascularization. These ﬁndings support the use of SES in TCO revas-
ularization. (The ACROSS/TOSCA Trial; NCT00378612). (J Am Coll Cardiol Intv 2009;2:97–106)
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98ompared with bare-metal stents, drug-eluting stents
DES) result in large and important reductions in angio-
raphic restenosis and the need for repeat revascularization
hen tested in restricted clinical trial cohorts. Beyond the
ontext of randomized trials with more restrictive enroll-
ent criteria, observational studies evaluating outcomes in
ess controlled and more complex cohorts have allowed
linicians to safely and routinely extend the use of DES to
broader percutaneous coronary intervention population.
Nonacute and chronic total coronary occlusions (TCOs)
emain a formidable challenge and unresolved dilemma in
he practice of interventional cardiology. In particular,
ercutaneous TCO revascularization is plagued by both
rimary and late failure. High rates of target lesion failure
fter use of balloon angioplasty or bare-metal stents in this
esion subset has been associated with impairment in left
entricular function, recurrent angina, repeat target vessel
evascularization, and the need for bypass surgery (1). The
otential for DES to improve long-term vessel patency after
CO recanalization is suggested by both the observed efficacy
f DES in less complex lesion subsets and by the historic
limitations of bare-metal stents in
TCO revascularization.
Preliminary reports describing
DES efficacy in TCOs are prom-
ising, with comparatively low rates
of restenosis and reocclusion (2–7).
However, reports describing rig-
orously obtained clinical and an-
giographic outcomes after DES
use in minimally selected TCOs
are lacking. Accordingly, we per-
formed the ACROSS/TOSCA-4
Approaches to Chronic Occlusions with Sirolimus-Eluting
tents/Total Occlusion Study of Coronary Arteries-4) study, a
ulticenter, nonrandomized prospective trial examining the
afety and efficacy of sirolimus-eluting stents (SES) in percu-
aneous TCO revascularization.
ethods
rial overview and study population. The ACROSS/
OSCA-4 trial was an investigator-initiated, prospective,
onrandomized multicenter trial evaluating the safety and
fficacy of treatment with SES in patients undergoing
lective percutaneous TCO revascularization at 15 hospitals
n North America (Online Appendix). The study was
pproved by the institutional review board at each site.
ligible patients signed written informed consent before the
nterventional procedure. To enable comparison with a
istorical control group treated with bare-metal stents,
linical and angiographic inclusion and exclusion criteria
ere modeled after those employed in the TOSCA-1
bbreviations
nd Acronyms
ES  drug-eluting stent(s)
ES  sirolimus-eluting
tent(s)
CO  total coronary
cclusion(s)
LR  target lesion
evascularizationTotal Occlusion Study of Canada-1) trial (8). Eligible fatients were age 18 years or older undergoing clinically
riven nonemergent percutaneous recanalization of a de
ovo occlusive coronary lesion exhibiting Thrombolysis In
yocardial Infarction (TIMI) flow grade 0 or 1 and judged
ble to accommodate an angioplasty balloon of 3.0-mm
iameter. Consenting patients were considered enrolled
pon successful crossing of the occluded segment with any
oronary guidewire and confirmation of guidewire place-
ent in the distal true lumen. Principal angiographic
xclusion criteria were in-stent total occlusions and excessive
essel angulation deemed by the operator likely to prohibit
tent delivery. There were no restrictions regarding lesion
ength. Clinical exclusion criteria were recent (72 h)
yocardial infarction, prior stent placement within the
arget vessel or any other vessel within 90 days of the index
rocedure, or any general contraindication to the revascu-
arization procedure and routine pharmacologic therapies.
nterventional procedure and adjunctive drug therapies. Pa-
ients were treated with the sirolimus-eluting Cypher cor-
nary stent (Cordis Corporation, Warren, New Jersey),
vailable in diameters ranging from 2.5 to 3.5 mm and in
engths from 8 to 33 mm. Placement of up to 2 33-mm SES
as permitted per protocol except in instances of insufficient
esion coverage or as a “bailout” procedure for dissection or
hrombus. All lesions were pre-dilated with balloon angio-
lasty, and the protocol specified that stent length should be
4 mm longer than the lesion for adequate coverage.
reatment with additional device therapies (e.g., atherec-
omy) was not permitted. Stents were expanded to achieve
10% residual stenosis by visual estimate throughout the
reated segment with use of supplemental post-deployment
alloon angioplasty left to operator discretion.
Prior to revascularization, all patients received treatment
ith aspirin (325 mg/day) and clopidogrel (75 mg/day) for
t least 48 h, followed by dual antiplatelet therapy for a
inimum of 3 months after the procedure and indefinite
spirin therapy. In those patients not receiving at least 48 h
f dual antiplatelet therapy before the procedure, a loading
ose of clopidogrel (300 to 600 mg) was given immediately
efore or during the procedure. Procedural antithrombin
nd intravenous glycoprotein IIb/IIIa inhibitor therapies
ere selected at the treating physician’s discretion but were
dministered according to protocol-recommended algorithms.
Clinical events were assessed during hospitalization and
t 30 days, 6 months, and planned annually for 5 years after
he index procedure. All patients were scheduled to undergo
ollow-up angiography at 6 months or sooner if the patient
eveloped angina or objective evidence of target vessel
schemia.
ata management and core laboratories. All data were
ubmitted to a central data coordinating facility (Duke
linical Research Institute, Durham, North Carolina).
oronary angiograms performed at baseline and atollow-up were reviewed by the independent angiographic
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99ore laboratory employed for TOSCA-1 (Cardiovascular
maging Research Core Laboratory, University of British
olumbia, Vancouver, British Columbia) and analyzed
sing the same methods (8). Standard image acquisition was
erformed using 2 or more angiographic projections of the
ccluded segment before and after stent placement. Com-
ulsory angiography was planned 180  30 days after the
rocedure using identical angiographic projections. Quan-
itative analysis of lumen dimensions was performed using
he Discovery system (Quinton, Bothell, Washington).
reated segment, or “working” length, represented the
ontiguous length of the target vessel occlusion exposed to
alloon inflation and was measured using images recorded
hroughout the procedure. Side branches, bends, and other
xed features were used to provide points of reference. A 5-
o 10-mm angiographically disease-free segment of refer-
nce diameter proximal and distal to the treated segment
as used to calculate the average reference vessel diameter
fter stent implantation and at follow-up. However, only
he proximal disease-free segment was used to calculate the
eference diameter at baseline in the context of total
cclusions or for other instances in which the distal refer-
nce vessel was poorly visualized. Moreover, to maintain
onsistency with comparison to the TOSCA-1 binary
estenosis rate in the treated segment, diameter stenosis was
alculated using a proximal reference diameter. Quantitative
nalysis was performed to evaluate the in-stent region
bordered by the stent margins) and the peristent, or
in-segment” region (in-stent region plus 5-mm margins
roximal and distal to the stent). For the latter 2 measures,
n average of both the proximal and distal reference diam-
ters were applied to calculate diameter stenosis.
tudy end points and deﬁnitions. The primary end point,
ngiographic restenosis within the entire treated segment,
as examined by quantitative coronary angiography at
-month follow-up. The treated segment was defined as the
ength of contiguous target segment exposed to balloon
ngioplasty pre-dilation, irrespective of stent placement.
ngiographic binary restenosis was defined as a stenosis
qual to or greater than 50% of the lumen diameter of the
arget lesion (determined by the core angiographic labora-
ory). Secondary angiographic end points included in-
egment late loss, failed patency (TIMI flow grade 3 and
70% in-segment diameter stenosis), reocclusion (TIMI
ow grade 0 or 1 at final angiography), and in-stent
estenosis.
Pre-specified clinical safety and efficacy end points in-
luded major adverse cardiac events (all-cause death, myo-
ardial infarction, and clinically driven target lesion revas-
ularization [TLR]) and its components reported at 30 days
months and at 1 year stent thrombosis (per protocol and
xpanded definition criteria [9]), clinically driven target
essel revascularization at 6 months and target vessel failure
cardiovascular death, myocardial infarction, and clinically sriven target vessel revascularization) at 6 months. Device
uccess was defined as a 50% diameter stenosis of the
arget lesion upon completion of the index procedure as
etermined by the core angiographic laboratory. Procedural
uccess was defined as device success and no in-hospital
ajor adverse cardiac events. Myocardial infarction was
efined as a creatine kinase elevation 2 times above the
pper limit of normal with any associated elevation in the
reatine kinase myocardial band or the development of new
athologic Q waves in 2 contiguous electrocardiographic
eads. Clinically driven revascularization was identified as
ny repeat revascularization of the target lesion or target
essel associated with either: 1) ischemic symptoms and/or
n abnormal functional study and a50% coronary stenosis
y quantitative angiography; or 2) any revascularization of a
70% diameter stenosis. All primary and secondary clinical
nd points were adjudicated by an independent clinical
vents committee.
Stent fracture was defined as an acquired discontinuity of
tent architecture within the originally stented segment. For
onsistency, and in view of the potential importance of this
henomenon with respect to late clinical events, all cinean-
iograms were reviewed for this occurrence. Consensus of 2
ndependent reviewers was required. Discordant results
ere resolved by consensus. This method differed from the
OSCA-1 trial, in which stent fracture was not prospec-
ively examined.
tatistical methods. The primary hypothesis of this study
as that compared with patients treated with bare-metal
tents in the TOSCA-1 study (N  202), patients treated
ith SES would show a 50% relative reduction in the
-month occurrence of the primary end point of angio-
raphic binary restenosis within the treated segment of the
arget vessel. Accordingly, enrollment criteria and trial
ethodology were modeled after the TOSCA-1 trial for
omparability. Under this assumption, with a sample size of
00 patients, the study had more than 95% statistical power
o determine statistical superiority of the primary end point
t a 1-sided 0.025 level of statistical significance.
To compare angiographic restenosis between patients
ncluded in the current and comparator trials, 2 pre-
pecified analytical methods were applied. In the primary
odel (10), outcomes were compared using an inverse
robability weighted analysis. This analysis used a propen-
ity score (11) that was calculated using 5 clinical and
ngiographic variables identified as predictors of angio-
raphic restenosis in prior randomized trials comparing
are-metal stents and DES (diabetes, reference vessel di-
meter, lesion length, age, current smoker status). A second
nalysis was completed using a propensity score constructed
ith 3 covariates (diabetes, reference vessel diameter, lesion
ength). In the secondary model, logistic regression was
pplied. Given the nonrandomized nature of this compari-
on, propensity score for study selection was calculated and
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100sed as an adjustment factor in the multivariable analysis,
hich also included other pre-specified clinical and angio-
raphic predictors of restenosis (e.g., diabetes, lesion length,
eference vessel diameter). Sensitivity analysis was applied to
ssess the influence of unmeasured confounders (12).
Patients were analyzed for all primary and secondary
fficacy and safety end points based on the intent-to-treat
rinciple. Patients who did not return for the 6-month
ngiographic follow-up had a restenosis value estimated
sing multiple imputations by study membership via the
arkov Chain Monte-Carlo method using PROC MI in
AS software (SAS Institute Inc., Cary, North Carolina).
Baseline characteristics of study patients were summa-
ized in terms of frequencies and percentages for categorical
ariables and by medians, 25th and 75th distribution per-
entiles for continuous variables. Categorical variables were
ompared by chi-square test and Fisher exact test when cell
izes were 5. Continuous variables were compared by the
-sample t test. A p value of 0.05 was established as the level
f statistical significance for all tests. Clinical and angio-
raphic predictors of restenosis were identified using multi-
ariable logistic regression. All analyses were performed
sing SAS software (version 8.2, SAS Institute).
esults
atient characteristics. Among 200 patients enrolled, all
atients except 1 received treatment with SES, and 1 SES
atient received additional treatment with a bare-metal
tent. Overall, the median age was 60.3 years, one-third had
history of myocardial infarction, and 24.5% had diabetes
ellitus (Table 1). Most (78.8%) were characterized as
aving a total occlusion exceeding 6 weeks of age. Nearly
alf of the target lesions were located in the right coronary
rtery, and most were proximal.
Consistent with more diffuse disease associated with
oronary total occlusions, the median (Q1, Q3) treated, or
orking length segment, as an indirect measure of TCO
esion length was 49.6 (33.4, 64.5) mm. Side branch
cclusions involving the TCO were present in 9.7% of
esions.
rocedural and in-hospital outcomes. The median stent
ength per target lesion was 45.9 (30.2, 62.1) mm. Three-
uarters of patients received at least 2 stents and 37% of
atients received 3 or more stents (Table 2). Procedural
uccess was achieved in 98% of patients (Table 2). Proce-
ural failure (hierarchal) was due to in-hospital adverse
vents (n  3), failure to achieve 50% residual stenosis
n  2), and/or inability to deliver only the assigned study
evice (n  1). Two cases of early repeat revascularization
ere performed exclusively for failure to achieve initial
atency in the target vessel.
ngiographic and clinical outcomes. Qualifying follow-up
ngiography was performed and suitable for core laboratory wnalysis in 170 (85.0%) patients. Clinical follow-up was
vailable in 196 patients (98.0%) at 180 days and 193
atients (96.5%) at 365 days. The primary end point,
estenosis within the entire treated segment, occurred in
2.6% (Table 3); rates of in-stent and segment restenosis
ere 9.5% and 12.4%, respectively. Among patients with
ngiographic in-stent restenosis, patterns of restenosis were
haracterized as focal (10 patients, 62.5%), diffuse intrastent
n 4, 25.0%), diffuse proliferative (none), and total occlusion
n  2, 12.5%). Rates of restenosis were higher among
atients with diabetes, longer durations of vessel occlusion,
nd those with longer stent lengths and overlapping stents
Fig. 1). Median late lumen loss was 0.10 (–0.57, 0.15)-mm
n-stent and –0.11 (–0.22, 0.37)-mm in-segment. Failed
atency at 6 months, defined as 70% stenosis with TIMI
ow grade 3 at angiographic follow-up, occurred in 2.9%
f patients, all of whom were identified with TIMI flow
rade 0 (n  2) or 1 (n  3).
Compared with a historical control of patients treated
Table 1. Baseline Patient Clinical and Angiographic Characteristics
Sirolimus-Stent Group
(N  200)
Clinical characteristics
Age, yrs 60.3 (54.8,69.7) (200)
Male, % 80.0 (160/200)
Diabetes mellitus, % 24.5 (49/200)
Hypertension, % 69.5 (139/200)
Age of occlusion 6 weeks 78.8 (119/151)
History of smoking, % 67.5 (135/200)
Hyperlipidemia, % 86.0 (172/200)
Prior myocardial infarction, % 33.5 (67/200)
Angina class III/IV, % 29.5 (59/200)
Heart failure class III/IV, % 4.5 (9/200)
Prior percutaneous revascularization, % 32.5 (65/200)
Prior coronary bypass surgery, % 8.5 (17/200)
Angiographic characteristics
Target vessel, %
Left anterior descending artery 29.5 (59/200)
Right coronary artery 49.0 (98/200)
Left circumﬂex artery 21.5 (43/200)
TIMI ﬂow grade 0/1, % 95.5 (191/200)
Moderate/severe calciﬁcation, % 46.4 (92/198)
Side branch occlusion, % 9.7 (3/31)
Reference vessel diameter, mm 2.93 (2.59, 3.30) (177)
Treated segment length, mm 49.60 (33.40, 64.50) (197)
Lesion location, %
Ostial/proximal 55.5 (111/200)
Mid 33.5 (67/200)
Distal 11.0 (22/200)
Values expressed as n (%) or median (Q1, Q3) (n). Angina and heart failure severity according to
Canadian Cardiovascular Society and New York Heart Association classifications, respectively.
TIMI Thrombolysis In Myocardial Infarction.ith bare-metal stents for TCO revascularization in the
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101OSCA-1 trial, patients treated with SES in the present
tudy had significantly smaller target vessel diameters, older
otal occlusions, longer lesions and stent lengths, and a
igher incidence of diabetes mellitus (Table 4). In univari-
ble analysis, total stent length per millimeter (p  0.008),
urrent smoking (p  0.01), diabetes (p  0.002), and
umber of stents implanted (p  0.046) were significant
redictors of in-stent angiographic restenosis. Despite
reater lesion complexity and clinical characteristics associ-
ted with angiographic restenosis, treatment with SES was
ssociated with an unadjusted 59% relative reduction in the
ngiographic primary end point (6-month treated lesion
ength restenosis rates: 55.2% TOSCA-1 trial vs. 22.6%
CROSS/TOSCA-4). The adjusted absolute reduction in
estenosis rates was 37.7% (95% confidence interval [CI]:
Table 2. Procedural Angiographic Results and In-Hospital Clinical Events
Sirolimus-Stent Group
(N  200)
Procedural characteristics
Number of stents 2.0 (1.5, 3.0) (196)
Stent length, mm 45.9 (30.2, 62.1) (199)
Stent diameter, mm 3.00 (2.75, 3.09) (196)
Inﬂation pressure, atm 16.0 (14.0, 18.0) (198)
2 stents implanted, % 75.0 (147/196)
Overlapping stents, % 92.0 (137/149)
Minimal luminal diameter, mm
Before procedure
In-lesion 0 (0, 0) (198)
After procedure
In-stent 2.43 (2.19, 2.75) (196)
In-segment 1.93 (1.53, 2.31) (196)
Treated segment 2.32 (1.96, 2.61) (197)
Diameter stenosis, %
Before procedure
In-lesion 100 (100, 100) (200)
After procedure
In-stent 9.0 (0, 17.0) (196)
In-segment 27 (19.0, 38.5) (196)
Treated segment 14.0 (4.5, 24.0) (196)
Device success, % 99.0 (198/200)
Procedural success, % 98.0 (195/199)
In-hospital outcomes
Death, % 0 (0/199)
Myocardial infarction, % 1.0 (2/199)
Q-wave, % 0 (0/199)
Non–Q-wave, % 1.0 (2/199)
Stent thrombosis, % 0 (0/199)
Target lesion revascularization, % 1.0 (2/199)
Nontarget lesion related target vessel
revascularization, %
0 (0/199)
Major adverse cardiac events, % 1.5 (3/199)
Values expressed as n (%) or median (Q1, Q3) (n).7.2 to 48.3, p  0.001) when adjusting for the 5-variableropensity score, and 36.4% (95% CI: 26.1 to 46.8, p 
.001) when adjusting for the 3-variable propensity score.
sing logistic regression adjusted for the 5-variable propen-
ity score, the relative reduction in odds of restenosis with
ES was 83% (odds ratio [OR]: 0.17, 95% CI: 0.09 to 0.30;
 0.0001) and similarly 84% (OR: 0.16, 95% CI: 0.09 to
.28; p  0.0001) in the 3-variable model. Aside from the
eduction in angiographic restenosis, the end point of failed
atency was also significantly reduced among patients
reated with SES (10.9% TOSCA-1 trial vs. 2.9%
CROSS/TOSCA-4, unadjusted p  0.005).
At 1 year, there were no deaths and no episodes of
ut-of-hospital myocardial infarction (Table 3). Major ad-
erse cardiac events were infrequent, occurring in 20
10.3%) patients most commonly due to repeat revascular-
zation. Similarly, the rate of target vessel failure was 10.9%.
t 6 months, 12 (6.0%) patients underwent repeat TLR,
ccounting for all repeat target vessel revascularization
Table 3. 6-Month Angiographic and 1-Year Clinical Outcomes
Sirolimus-Stent Group
(N  200)
Quantitative angiography
Late lumen loss, mm
In-stent 0.10 (–0.57, 0.15) (146)
In-segment –0.11 (–0.22, 0.37) (146)
Treated segment 0.04 (–0.49, 0.23) (146)
Minimal luminal diameter, mm
In-stent 2.27 (1.89, 2.69) (147)
In-segment 2.02 (1.65, 2.37) (147)
Treated segment 2.13 (1.80, 2.56) (146)
Diameter stenosis, %
In-stent 18.0 (9.0, 33.5) (168)
In-segment 30.5 (19.0, 42.0) (169)
Treated segment 32.0 (21.0,47.0) (168)
Binary restenosis, %
In-stent 9.5 (16/169)
In-segment 12.4 (21/169)
Treated segment 22.6 (38/168)
Failed patency, % 5/168 (2.9%)
Clinical events
Death, % 0 (0/193)
Myocardial infarction, % 1.0 (2/193)
Q-wave, % 0 (0/193)
Non–Q-wave, % 1.0 (2/193)
Stent thrombosis, % 1.0 (2/193)
Target lesion revascularization, % 9.8 (19/193)
Percutaneous 8.8 (17/193)
Surgical 1.0 (2/193)
Target vessel revascularization–not involving
target lesion, %
1.6 (3/193)
Target vessel failure, % 10.9 (21/193)
Major adverse cardiac events, % 10.3 (20/193)Values expressed as n (%) or mean ( SD).
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102rocedures during that period. By 1 year, TLR occurred in
n additional 7 patients, contributing to an overall rate of
.8%.
Adherence to dual antiplatelet therapy at 6- and 12-
onth follow-up was documented for 93.7% (177 of 193)
nd 83.1% (157 of 189) patients, respectively. By 1 year,
tent thrombosis per protocol angiographic definition was
djudicated for 2 patients. There were no probable or
ossible stent thrombosis events (9). In the first episode,
onocclusive thrombus was identified during protocol-
andated angiographic follow-up 115 days after the index
evascularization and resulted in repeat percutaneous revas-
ularization. In the second event, thrombus was identified in
side branch related to the target segment immediately after
he index procedure. At 236 days, the patient underwent
ercutaneous revascularization in non-target vessel–related
erritories. Angiography showed persistence of side branch
hrombus and a patent target vessel stent in an asymptom-
tic patient. Neither event was associated with ischemic
Figure 1. In-Stent Angiographic Binary Restenosis Among Selected Patient
Rates of 6-month angiographic in-stent binary restenosis for selected patient s
durations of vessel occlusion, and those with longer stent lengths and overlap
Table 4. Comparison of Selected Patient Characteristics Between ACROSS
ACROSS/
(N 
Age, yrs 60.3 (54.8, 6
Age of occlusion 6 weeks, % 78.8 (119/1
Reference vessel diameter, mm 2.93 (2.59, 3
Current smoker, % 17.5 (35/20
Diabetes, % 24.5 (49/20
Male, % 80.0 (160/2
Hypertension, % 69.5 (139/2
Target vessel: left anterior descending artery, % 29.5 (59/20
Stent length, mm 45.8 (30.2, 6
Treated segment length, mm 49.6 (33.4, 6Values expressed as n (%) or median (Q1, Q3) (n).ymptoms or abnormal biomarker findings related to the
arget vessel.
Coronary angiograms were independently reviewed by 2
xaminers for stent fracture and adjudicated by consensus.
mong 32 patients (16%) identified with definite or prob-
ble stent fracture (56 events; 44 definite, 12 probable)
uring angiographic follow-up, in-stent angiographic reste-
osis occurred in 5 patients (Table 5). Characteristics
ommon to patients identified with stent fracture included
ight coronary artery location (84%), significant (45°)
essel angulation (23%), and/or stent placement in regions
f extreme dynamic motion (14%). Compared with patients
ot observed with stent fracture, those identified with stent
racture had significantly greater total stent length. Al-
hough infrequent, rates of in-stent and -segment binary
estenosis were approximately 2-fold higher for patients
ith stent fracture compared with non-stent fracture pa-
ients. However, restenosis at the site of stent fracture
ccurred in only 2 of the 5 patients, although 1 patient
roups
ups. Rates of restenosis were higher among patients with diabetes, longer
tents. DM  diabetes mellitus.
CA-4 and TOSCA-1 Trial Populations
-4 TOSCA-1
(N  202) p Value
00) 57.7 (50.0, 65.7) (202) 0.001
36.6 (48/131) 0.001
77) 3.31 (2.93, 3.71) (201) 0.001
17.8 (36/202) 0.93
14.9 (30/202) 0.02
83.7 (169/202) 0.34
34.7 (70/202) 0.001
38.6 (78/202) 0.05
98) 28.0 (15.0, 42.0) (193) 0.001
97) 31.4 (20.0, 46.5) (202) 0.001Subg
ubgro/TOS
TOSCA
200)
9.7) (2
51)
.30) (1
0)
0)
00)
00)
0)
2.1) (1
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103xperienced restenosis at 2 separate fracture sites. Among all
ases of stent fracture, 41% were localized to the body of the
tent, and 59% were identified in or immediately adjacent to
he segment of overlapping stents. There was no associated
neurysm formation. At 1-year follow-up, TLR was signif-
cantly more common in patients identified with stent
racture (25.0% vs. 6.7%, p  0.005) (Table 5), yet repeat
evascularization at the site of fracture occurred only in 3 of
patients.
iscussion
n this prospective evaluation of the clinical efficacy, safety
nd angiographic outcomes among patients treated with
ES in complex TCO revascularization, percutaneous re-
ascularization with SES resulted in substantial reductions
n angiographic restenosis and failed patency and a low rate
f repeat revascularization. Treatment with SES led to these
esults despite the presence of higher-risk patients and more
omplex lesion characteristics compared with a historical
are-metal stent control. These findings further support the
se of SES in TCO revascularization.
Unlike the widespread evaluation of DES beyond ap-
roved patient and lesion indications, until recently, few
nvestigations have been performed to support the clinical
enefit of DES in total occlusion revascularization. In
articular, our understanding of procedural and mid-term
afety and efficacy of DES after TCO revascularization has
een limited by the routine exclusion or under-
epresentation of such patients in most major interventional
ardiology clinical trials. Despite greater lesion complexity
han in prior TCO trials, treatment with SES was associ-
ted with a significant 37% absolute rate reduction and
85% relative reduction in the odds of angiographic reste-
osis compared with patients treated with conventional
are-metal stents in a similar clinical setting and after
omparison adjusted for propensity scores for clinical and
ngiographic characteristics. Considering, for example, that
Table 5. Comparison of 6-Month Angiographic and 1-Year Clinical Characte
Stent Fracture
(n  32)
Stent length, mm 65.5 (49.7, 73.6)
Overlapping stents, % 100 (30/30)
Procedural success, % 100.00 (32/32)
Target lesion revascularization, % 25.0 (8/32)
Major adverse cardiac events, % 25.0 (8/32)
Stent thrombosis, % 3.2 (1/31)
Binary restenosis, %
In-segment 25.0 (8/32)
In-stent 15.6 (5/32)
Values expressed as n (%) or median (Q1, Q3) (n).he median-treated lesion length and stent length in the surrent study were 49.6 mm and 45.9 mm, respectively,
atients included in this trial represent one of the most
hallenging lesion subsets evaluated with DES treatment.
owever, despite more complex lesion morphology in
ontrast to patients treated with bare-metal stents (e.g.,
lder total occlusion duration, smaller reference vessel cali-
er, longer lesion and stent length) and a higher frequency
f diabetes—characteristics predictive of angiographic and
linical restenosis—percutaneous revascularization with
ES resulted in very favorable rates of in-stent binary
estenosis (9.5%) and 1-year TLR (9.8%). Moreover, these
esults were observed in the context of a relatively high rate
f protocol-specified follow-up angiography. These findings
re similar to the smaller, randomized PRISON II (Primary
tenting of Totally Occluded Native Coronary Arteries II)
tudy (SES treatment, N  100), in which treatment with
ES resulted in a 6-month angiographic binary restenosis
ate of 7.0%, a 73% relative reduction in in-segment
estenosis compared with bare-metal stents and a 5.0%
ncidence of repeat TLR (2). In the present study, however,
he slightly higher 1-year rate of repeat revascularization is
ikely attributed to substantially greater patient clinical and
esion complexity (e.g., 2.5-fold increase in diabetes, 3-fold
ncrease in lesion length, 1.5-fold increase in average num-
er of stents).
Compared with prior retrospective, observational studies
valuating DES treatment in patient subgroups of a larger
tudy population and with more variable angiographic
urveillance (3–7), methods in the present study also differed
y the assessment of lesion length treated in the occluded
egment. In particular, evaluation of restenosis according to
he entire treated segment, in addition to more contempo-
ary measures within the stent and peristent regions, not
nly reflects a revascularization technique that is unique to
CO revascularization but may also be more clinically
elevant. Because assessment of disease adjacent to the
ccluded segment is not routinely visible, and the entire
s Between Patients With and Without Stent Fracture
Nonstent Fracture
(n  168) p Value
41.9 (28.8, 57.0) 0.001
89.9 (107/119) 0.06
97.6 (163/167) 1.00
6.7 (11/162) 0.005
7.4 (12/161) 0.007
0.6 (1/162) 0.30
9.5 (13/137) 0.017
8.0 (11/137) 0.17risticegment pre-dilated with balloon angioplasty is not always
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104reated with stent placement once antegrade flow is restored
nd visibility improved, assessment of outcomes within the
reated segment may more accurately reflect outcomes after
CO revascularization than those limited to the in-stent
egment. Perhaps due to an angiographically acceptable
esult with balloon angioplasty alone, and/or a reluctance to
erform more extensive stenting, a longer disease segment
as treated with angioplasty than with stenting so that
hen restenosis did occur, it was considerably more com-
on in regions beyond the stent margins. Such findings
ave implications in routine clinical practice, suggesting that
ore extensive atherosclerosis associated with total occlu-
ions may be better treated with SES rather than with
ngioplasty alone or bare-metal stents (13).
An additional study method unique to this trial was the
rospective assessment for coronary stent fracture, which
as characterized after adjudicated review of follow-up
ngiograms as definite or probable for 32 patients (Fig. 2).
Figure 2. Coronary Stent Fracture Following TCO Revascularization With S
Transverse, disarticulated stent fractures in the right coronary artery identiﬁed
(closed arrows, C) compared with baseline imaging following total coronary o
arrows, A, B).lthough more commonly identified after lower limb re- iascularization with stents, coronary stent fracture is a more
ecent observation for which the cause and outcome are not
ell understood. Consistent with a prior descriptive study,
tent fracture is most commonly associated with increasing
tent length and in coronary segments identified with
ignificant angulation or dynamic flexure before stenting
e.g., right coronary artery) (14). No stent fractures were
dentified in the TOSCA-1 trial, in which patients were
reated with shorter (e.g., 15-mm length) stents, leading to
ignificantly shorter total stent length. Thus, the current
esults may reflect an interaction between longer, overlap-
ing stent segments and more regions of dynamic flexure, in
omparison with TOSCA-1. In accord with 6-month rates
f restenosis that were approximately twice as common
hen compared with patients without fracture, the 1-year
epeat revascularization was significantly higher among
atients with stent fracture. However, it is difficult to fully
eparate the role of stent length from that of stent fracture
s-Eluting Stents
onth angiography (bracketed arrows, D) with insigniﬁcant focal restenosis
on (TCO) revascularization with 4 contiguous, overlapping stents (whiteirolimu
at 6-m
cclusin the genesis of restenosis in this study because there was a
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105ignificantly longer stent length in the fracture group (66
m vs. 42 mm), and yet restenosis at the fracture site was
dentified in only 2 patients.
tudy limitations. In the absence of randomization, a limi-
ation to this analysis is that despite the use of a propensity
core methodology, the possibility that measured or unmea-
ured confounders may have affected the results of the study
annot be excluded. However, this issue has been addressed
y adjusting for pre-specified known predictors of angio-
raphic restenosis in propensity score analyses, and per-
orming sensitivity analyses to evaluate the influence of
ossible unmeasured confounders on the study results. All
nalyses showed consistent evidence of superiority of SES
ompared with bare-metal stents in the TOSCA-1 study. In
ddition, although analysis of angiographic and clinical
utcomes was similar between trials, the primary end points
iffered between the current study (angiographic binary
estenosis) and the TOSCA-1 trial (failed patency). How-
ver, failure of sustained patency, a secondary end point in
his trial, was also significantly reduced with SES compared
ith the bare-metal stent control. Also, in comparison with
ome prior studies of occluded arteries, not all TCOs were
stimated as “chronic” in age. To our knowledge, the
stimated age of a TCO has historically been related to
echnical success of recanalization rather than later term
ngiographic or clinical outcomes. Nevertheless, approxi-
ately 20% of patients in the present study had a TCO age
stimated 6 weeks, although this proportion is consider-
bly lower than the TOSCA-1 trial and more recent total
cclusion studies (2,8). Finally, an association between stent
racture and clinical outcome should be considered hypoth-
sis generating given that the temporal association between
fracture and an adverse event was not established for all
atients. Diagnostic accuracy for stent fracture may also vary
ccording to method (e.g., fluoroscopy, intravascular ultra-
ound), and limiting analysis to fluoroscopy alone may have
nderestimated its incidence. Without an established
ethod to identify this finding, we performed independent
eviews by 2 examiners with adjudication by a third reviewer
n instances of disagreement. In our experience, there was a
4% agreement between the 2 initial reviewers with adju-
ication required in 26% of cases. In nearly all instances
equiring adjudication, the disagreement was not related to
hether fracture was present but rather qualifying the
racture severity (e.g., partial vs. complete).
onclusions
mprovement of long-term restenosis-free patency with
ES in TCOs has potentially significant clinical influenceonsidering the persistently high rates of target lesion failureith bare-metal stents and the association of failure to
chieve or sustain patency of TCOs with impairment in left
entricular function, recurrent angina, repeat target vessel
evascularization, and a greater need for late bypass surgery
1). Further, the 4-fold reduction in failed patency with SES
ompared with bare-metal stents may conceivably influence
linical outcome given that patency is likely to be an even
ore important predictor of late clinical events than mere
estenosis. For the period studied, treatment with SES as
art of TCO revascularization appeared safe, with a low
requency of periprocedural myocardial infarction and no
eaths. Although there were only 2 episodes of angiographi-
ally identified thrombosis (1 instance limited to a target
essel side branch outside of the stent itself), it is notable
hat these were observed against a background of high
dherence (80% at 1 year) to a dual antiplatelet regimen.
inally, stent fracture was not associated with stent throm-
osis or aneurysm formation, and the site of stent fracture
as uncommonly the culprit site of restenosis or TLR
espite higher rates of repeat revascularization in this
atient group. Dedicated long-term follow-up will further
larify the late safety and efficacy of DES treatment in this
omplex lesion subset, including the longer term impact of
tent fractures. Even so, the results suggest that treatment
ith SES should be favored for percutaneous revasculariza-
ion in chronically occluded native coronary arteries.
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APPENDIX
or a list of the ACROSS/TOSCA-4 trial study sites and principal investi-
ators, please see the online version of this article.
